glp-1 agonist. Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review How GLP-1 Receptor Agonists Evolved
Description
CPAA (2022) 14:1926
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
A Meta-Analysis of Serious Adverse Events Reported With Exenatide and Liraglutide: Acute Pancreatitis and Cancer
Most titration schedules start at 1-2mg for the first month, increase to 4mg for month two, then reach 8mg or 12mg by month three
There were no ICP lowering agents or addition of headache preventative drugs started during the study
Complete information on authors, methodology and conflicts of interest is available in the published paper
